Programme

Valid as of 02 July 2020
15:50 - 16:00
Opening

16:00 - 16:45
Case Based Learning for the Heart Team: coronary artery disease in TAVI patients

Attend this session if you want:
- To fully understand the practical implications of coronary artery disease in TAVI patients
- To recognise different situations where this interaction directly impacts on clinical outcomes
- To appreciate how to apply this information in your daily clinical practice

16:00
Session objectives
J. Fajadet

16:02
Coronary artery disease in TAVI patients - What are the issues?
S. Kodali

16:12
Case 1: a patient with significant coronary artery disease who needs TAVI
S. Redwood

16:17
Discussion
J. Fajadet, S. Redwood

16:22
Case 2: a patient undergoing TAVI who is at high risk of coronary occlusion
H. Eltchaninoff

16:27
Discussion
J. Fajadet, H. Eltchaninoff

16:32
Case 3: a patient with a TAVI device who needs urgent PCI
A. Latib

16:37
Discussion
J. Fajadet, A. Latib

16:42
Session evaluation and key learnings
J. Fajadet

16:00 - 16:41
Mitral interventions - part 1

16:00
Early experience with the EVOQUE mitral valve replacement system
J. Webb

16:06
Comprehensive mitral valve-in-valve and valve-in-ring analysis
M. Simonato

16:12
Two-year outcomes of Tendyne TMVI
D. Muller

16:20
Six-month and one-year outcomes with the novel PASCAL transcatheter valve repair
J. Webb

16:26
Feasibility study of Tendyne mitral valve system in mitral annular calcification
P. Sarrajia

16:32
My analysis of EVOQUE replacement, repair with PASCAL, Tendyne, V-i-V and V-i-R
F. Maisano
**Hot lines and innovations**

16:00 - 19:00

- **Advances in coronary stenting - Outcome of thinnest strut DES**
  K. Sivaprasad
- **TARGET All Comers Trial- three-year Results**
  A. Lansky
- **Final results of the REMEDEE registry**
  L. Kerkmeijer
- **e-ULTIMASTER registry: final results and differences across continents**
  M. Roffi
- **One-year clinical outcomes of complex PCI treated with use of Ultimaster stent**
  M. Mamas
- **Main results of the Biofreedom QCA trial**
  M. Sabate
- **Bariatric embolotherapy for obesity: a pilot single-blind sham-procedure RCT**
  V. Reddy
- **Phase-one results from the Venus HF - preCARDIA device trial**
  N. Kapur
- **Pulmonary artery denervation: 12-month results of the TROPHY study**
  A. Rothman
- **The SIBERIA trial for carotid artery stenosis**
  P. Ignatenko
- **ANGIE trial**
  G. Tsigkas
- **Prevention of AKI with sodium bicarbonate**
  M. Zimarino
- **Bifurcation stenting: role of deployment technique in a global registry**
  B. Chevalier
- **Gender differences in outcomes after rational atherecomy PCI**
  P. Fousset
- **Intensified antiplatelet therapy in post-PCI patients with HOPR**
  C. Li
- **Safety and efficacy of the TaurusOne TAVR system for aortic stenosis**
  Y. Wu
- **A multicentre clinical study of LEFTEAR LAAC device**
  Y. Xu
- **Analysis of changes in decision-making process during OCT-guided PCI**
  H.G. Bezerra
- **Functional results following DCB vs. DES in small coronary vessels**
  Z. Jin
- **V-LAP system: first-in-human experience**
  D. D’Amaro
- **Hybrid transcatheter left ventricular reconstruction: mid-term results**
  P. Klein
- **Sirolimus-eluting balloon for vasculogenic erectile dysfunction**
  G. Sangiorgi

**Clinical cases**

16:00 - 19:00

- **ACS-patient with culprit in a coronary ectasia**
  M. Didagelos
- **Coronary stenting in an ectatic artery**
  R.J. Van Geuns
- **Challenging PCI after aortic valve-in-valve implantation**
  A. Aliali
- **A life-saving myocardial infarction**
  M. Wadie
- **Cisplatin-induced coronary artery thrombosis presented as ACS**
  S. Agstam
- **AngioVac thrombectomy in a large and mobile right atrial thrombus**
  C. Kaymaz
- **Appearances can be deceiving, a story of a right coronary artery IVUS-guided PCI**
  M. Wadie
- **Life is all about how well you handle plan B**
  M. Wadie
- **MOCA I study: microvascular obstruction measured using dMVR**
  F. Gragnano
- **The many faces of in-stent restenosis**
  J. Mailey
- **When the medical history can guide the therapeutic choices**
  G. Valenti
- **Complex CTO case resolved by multiple techniques and technologies**
  B. Faurie
# Abstracts

## Abstracts

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>Use of the FlexNav delivery system in challenging horizontal aortic anatomy</td>
<td>B. Chehab</td>
</tr>
<tr>
<td>16:00</td>
<td>PCI with robotic assistance: the first 100 patients at Clinique Pasteur</td>
<td>C. Laparcer</td>
</tr>
<tr>
<td>16:00</td>
<td>The effects of shockwave lithotripsy on DES</td>
<td>C. Ada</td>
</tr>
<tr>
<td>16:00</td>
<td>5-year data of the drug-eluting absorbable metal scaffold in BIOSOLVE-II</td>
<td>M. Haude</td>
</tr>
<tr>
<td>16:00</td>
<td>LVESD determines anatomic suitability for TMVI</td>
<td>L. Conradi</td>
</tr>
<tr>
<td>16:00</td>
<td>Characteristics and outcomes of patients with severe MR ineligible for TMVR</td>
<td>S. Ludwig</td>
</tr>
<tr>
<td>16:00</td>
<td>Virtual stenting algorithm from FFR pullback: a proof of concept study</td>
<td>J.F. Argacha</td>
</tr>
<tr>
<td>16:00</td>
<td>Hemodynamic assessment of patients with severe AS and normal EF undergoing TAVI</td>
<td>A. Allali</td>
</tr>
<tr>
<td>16:00</td>
<td>12-month follow-up results of the first cohort of the BIOSOLVE-IV registry</td>
<td>M.K.Y. Lee</td>
</tr>
<tr>
<td>16:00</td>
<td>Thromboreistance of DES in a swine shunt model under clopidogrel monotherapy</td>
<td>Y. Sato</td>
</tr>
<tr>
<td>16:00</td>
<td>Three-year result of the Global Symplicity registry: impact of medication burden</td>
<td>F. Mahfoud</td>
</tr>
<tr>
<td>16:00</td>
<td>Percutaneous mitral edge-to-edge repair in cardiogenic shock</td>
<td>R. Estevez-Laureiro</td>
</tr>
<tr>
<td>16:00</td>
<td>One-year outcomes with the ACURATE neo valve system in the PROGRESS PVL registry</td>
<td>W.K. Kim</td>
</tr>
<tr>
<td>16:00</td>
<td>Safety and effectiveness of lithotripsy in calcified eccentric coronary lesions</td>
<td>H. Nel</td>
</tr>
<tr>
<td>16:00</td>
<td>PICSO improves coronary microvascular function in patients with STEMI</td>
<td>R. Scarsini</td>
</tr>
<tr>
<td>16:00</td>
<td>TMVI with Tiara: transapical results and transseptal design</td>
<td>L. Conradi</td>
</tr>
<tr>
<td>16:00</td>
<td>Paclitaxel DEB for coronary lesions: 12-month results of the PREVAIL study</td>
<td>A. Latib</td>
</tr>
<tr>
<td>16:00</td>
<td>Clinical and haemodynamic outcomes after self-expanding TAVR in failed SAVs</td>
<td>D. Holzhey</td>
</tr>
<tr>
<td>16:00</td>
<td>FORWARD PRO one year</td>
<td>S. Windecker</td>
</tr>
<tr>
<td>16:00</td>
<td>Constant resistance ratio of a pressure microcatheter validated using iFR</td>
<td>C. Li</td>
</tr>
<tr>
<td>16:00</td>
<td>Bailout stenting post drug coated balloons; Synergy or toxicity?</td>
<td>S. Basavarajiah</td>
</tr>
<tr>
<td>16:00</td>
<td>Sirolimus-eluting balloon vs sirolimus-eluting stent in diabetic patients</td>
<td>L. Testa</td>
</tr>
</tbody>
</table>

## Latest insights from the ReCre8 randomised trial

See session details in the Sponsored Programme section at the end of this document.

## Benefits of ultrathin DES in complex bifurcations - case based expert discussion

See session details in the Sponsored Programme section at the end of this document.

## Latest experience with PiCSO in STEMI patients

See session details in the Sponsored Programme section at the end of this document.

## LAA occlusion vs. novel oral anticoagulation in atrial fibrillation

See session details in the Sponsored Programme section at the end of this document.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 20:30</td>
<td>Advances in the renal denervation procedure</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>Shockwave IVL Safety and Performance in Eccentric Calcified Coronary Lesions</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>Results from XTOSI Trial: MagicTouch SCB - Future Alternative for PVD Treatment</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>Microcatheter-based coronary physiology: where and how</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>The new paradigm for coronary interventions</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>LAA occlusion vs. novel oral anticoagulation in atrial fibrillation</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>Proximal optimisation technique (POT) in bifurcation stenting</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td></td>
<td>The unique challenges of left main PCI</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Addressing the population question - interesting case profiles in renal denervation</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Renal denervation: putting guidelines into practice</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>TAVI implantation optimisation - Practical aspects of cusp overlap technique</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Post-TAVI PCI access - The essentials</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Treating bicuspid valve anatomy - evidence and practice</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Durability of Transcatheter Aortic Valves</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>The dynamic landscape of mitral interventions in 2020</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Latest advances in CTO techniques</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
</tbody>
</table>
Thursday 25 June 2020

16:00 - 20:30

Evidence based PCI in patients at high bleeding risk - The LEADERS FREE trials

See session details in the Sponsored Programme section at the end of this document.

16:00 - 20:30

Use of IVUS+NIRS imaging for decision making in ACS

See session details in the Sponsored Programme section at the end of this document.

16:02 - 16:18

Advances in pharmacological treatment of SARS-CoV2: ongoing and planned clinical trials

State-of-the-art lecture
P.G. Steg

16:21 - 17:22

Optimal left main bifurcation stenting technique: a patient-centred approach
Facilitators: J. Fajadet, T. Lefevre, G. Stankovic

Attend this session if you want:
- To learn how to adopt left main treatment strategy to the underlying anatomy
- To understand when a two-stent strategy should be selected
- To learn tips and tricks of the TAP stenting technique
- To discuss how to solve technical difficulties at each step of the procedure

16:41 - 17:32

Hot line: TAVI - part 1

- Full one-year Evolut low-risk randomised results and economic implications
  M. Reardon
- Safety, effectiveness of next-generation balloon-expandable THV: MyVal-1 study
  R.S. Rao
- BASILICA vs. control in TAVI procedures at risk for coronary obstruction
  D. Dvir
- Non-invasive ultrasound therapy for aortic stenosis
  A. Ijsselmuiden
- First evaluation of long-term outcomes after aortic valve-in-valve procedures
  D. Dvir
- My analysis of Evolut low-risk, MyVal-1, BASILICA, non-invasive ultrasound, ViV
  N. Dumonteil

16:45 - 17:30

Emerging from the SARS-COV-2 crisis: using immersive team simulation to optimise safety and outcomes
Speakers: R. Al-Lamee, I. Malik, D. Sparv

Attend this session if you want:
- To learn how to integrate simulation in your own cathlab
- To experience crisis management- maintain quality and safety without training on real people
- To optimise multidisciplinary team working
- To use simulation to develop new processes during a pandemic

17:24 - 17:34

Commando not required
"Imaging for complex structural heart interventions"

See session details in the Sponsored Programme section at the end of this document.
17:30 - 17:45  
**CASE-BASED LEARNING CHANNEL**  
**Level**  
**Sponsored session**  
A pivotal moment for renal denervation  
See session details in the Sponsored Programme section at the end of this document.

17:45 - 18:15  
**CASE-BASED LEARNING CHANNEL**  
**Level**  
**Spotlight**  
Basics of peripheral interventions  
*Speakers: B. Honton, A. Sauguet*  
Attend this session if you want:  
› To deal with a complex cross over  
› To know how to treat a long superficial femoral artery occlusion  
› To discuss how to decide material to use after POBA in long SFA occlusive disease

17:32 - 17:51  
**HOTLINE AND INNOVATION CHANNEL**  
**Level**  
**Focus on Innovation**  
**Spotlight**  
Update on the regulation of high-risk medical devices: a transatlantic perspective  
*Speakers: R. Byrne, A. Farb, P. Piscoi*  
Attend this session if you want:  
› To provide an update on new developments in the regulation of high-risk medical devices in Europe and the United States  
› To discuss opportunities for physicians to become more involved in the regulatory environment  
› To discuss the types of clinical evidence considered in the regulation of high risk medical devices

17:51 - 18:10  
**MAIN ARENA CHANNEL**  
**Level**  
**State-of-the-art lecture**  
Update on interventional treatment of ischaemic stroke  
*Speaker: P. Widimsky*

17:36 - 17:42  
**MAIN ARENA CHANNEL**  
**Level**  
**Focus on Imaging**  
**Sponsored session**  
How to easily reduce radiation exposure in your cathlab? 5 minutes to convince  
See session details in the Sponsored Programme section at the end of this document.

17:44 - 17:49  
**MAIN ARENA CHANNEL**  
**Level**  
**Focus on Imaging**  
**Sponsored session**  
Robotic PCI programme in IGS 5 environment  
See session details in the Sponsored Programme section at the end of this document.

17:51 - 18:19  
**HOTLINE AND INNOVATION CHANNEL**  
**Level**  
**Focus on Innovation**  
**Hot line / Late-Breaking Trials**

17:51  
*Transfemoral TTVR with EVOQUE for severe TR*  
N. Fam

17:58  
*Study of transcatheter tricuspid annular repair*  
W. Hennemann

18:05  
*One-year TRILUMINATE trial results*  
P. Lurz

18:12  
*My analysis of Evoque FIM and repair techniques for tricuspid regurgitation*  
N. Piazza

18:12 - 18:57  
**MAIN ARENA CHANNEL**  
**Level**  
**Recorded LIVE Case**  
Procedural techniques for TAVI  
*Facilitators: A. Baumbach, N. Dumonteil, N. Karam*  
Attend this session if you want:  
› To understand what are the crucial steps of TF TAVI that have been improved to optimise outcomes
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Channel</th>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
</table>
| 18:15 - 19:00 | Prevention and management of coronary complications                     | CASE-BASED LEARNING CHANNEL                  | Level       | Attend this session if you want:  
To discuss cases with different PCI-related complications  
To learn how to minimize their risks  
To discuss how to best manage them  
Post complex PCI and heart failure - an unexpected complication of rotational atherectomy  
B. Thevan  
What did we learn from this case?  
G. G. Toth, B. Thevan  
A patient with STEMI and giant coronaries  
T. Johnson  
What did we learn from this case?  
G. G. Toth, T. Johnson  
A patient with no-reflow after stent post-dilatation in STEMI  
P. Capranzano  
What did we learn from this case?  
P. Capranzano, G. G. Toth  
An unusual cause of STEMI  
A. Ryding  
What did we learn from this case?  
G. G. Toth, A. Ryding |
| 19:00 - 19:45 | SYNERGY MEGATRON - Transforming your left main bifurcation strategy for improved outcomes | CASE-BASED LEARNING CHANNEL                  | Level       | See session details in the Sponsored Programme section at the end of this document. |
| 18:19 - 19:10 | Mitral interventions - part 2: Global EXPAND registry                  | HOTLINE AND INNOVATION CHANNEL               | Level       | Safety and effectiveness outcomes with MitraClip XTR system  
M.J. Price  
Clip selection strategy and outcomes with MitraClip (NTR/XTR)  
F. Maisano  
Clinical outcomes with MitraClip (NTR/XTR): core-lab echo results  
W. Rottbauer  
Mitra valve leaflet adverse events with MitraClip  
F. M. Asch  
My analysis of Global EXPAND registry  
A. Vahanian |
| 19:00 - 19:45 | How the interventional cardiologist should approach patients with a vasculogenic erectile dysfunction? | HOTLINE AND INNOVATION CHANNEL               | Level       | See session details in the Sponsored Programme section at the end of this document. |
| 19:00 - 19:45 | Target all comers outcomes update                                      | INTERVIEWS AND ROUND TABLE CHANNEL           | Level       | See session details in the Sponsored Programme section at the end of this document. |
| 19:00 - 20:30 | Best real-world applications of Shockwave intravascular lithotripsy (IVL) in coronary calcium | MAIN ARENA CHANNEL                           | Level       | See session details in the Sponsored Programme section at the end of this document. |

Thursday 25 June 2020

Interventions for Valvular Disease  
Coronary interventions  
Interventions for Heart Failure  
Interventions for Hypertension  
Interventions for Stroke  
Peripheral Interventions
Thursday 25 June 2020

19:45 - 20:45
Selection of appropriate devices for retrograde CTO cases
See session details in the Sponsored Programme section at the end of this document.

19:45 - 20:30
FFR wires passé? Rethinking the physiological assessment of coronary artery disease
See session details in the Sponsored Programme section at the end of this document.

20:02 - 20:48
Are Lower MR Grades Within Our "Clasp"? - PASCAL Repair System Experience
See session details in the Sponsored Programme section at the end of this document.

20:48 - 20:58
Key learnings of the day
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Channel</th>
<th>Level</th>
<th>Sponsored</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:09 - 12:14</td>
<td>Introduction of the day</td>
<td>MAIN ARENA CHANNEL Level</td>
<td>Spotlight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:16 - 12:16</td>
<td>Coronary Microvascular Dysfunction: Why diagnosis in the Cathlab does matter</td>
<td>MAIN ARENA CHANNEL Level</td>
<td>Level</td>
<td>Sponsored</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>12:30 - 13:15</td>
<td>Current evidence for the interventional treatment of INOCA patients</td>
<td>CASE-BASED LEARNING CHANNEL Level</td>
<td>Level</td>
<td>Sponsored</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>12:30 - 13:15</td>
<td>Sirolimus-coated balloons, an appraisal on its potential advantages over paclitaxel</td>
<td>HOTLINE AND INNOVATION CHANNEL Level</td>
<td>Level</td>
<td>Sponsored</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>12:30 - 17:30</td>
<td>Do drug-coated balloons prevail?</td>
<td>INTERVIEWS AND ROUND TABLE CHANNEL Level</td>
<td>Level</td>
<td>Sponsored</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>13:15 - 14:00</td>
<td>Mastering complex calcified aortic stenosis</td>
<td>CASE-BASED LEARNING CHANNEL Level</td>
<td>Level</td>
<td></td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>13:15 - 14:00</td>
<td>New TMVI therapy to eliminate mitral regurgitation. Evidence and patient selection</td>
<td>HOTLINE AND INNOVATION CHANNEL Level</td>
<td>Level</td>
<td>Sponsored</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
<tr>
<td>13:18 - 14:00</td>
<td>How to treat complex bifurcation lesions? From bench to being</td>
<td>MAIN ARENA CHANNEL Level</td>
<td>Level</td>
<td>Sponsored</td>
<td>See session details in the Sponsored Programme section at the end of this document.</td>
</tr>
</tbody>
</table>
**Prevention and management of complications during valvular and structural interventions**

Attend this session if you want:
- To understand how to avoid complications
- To assess how to recognize complications early
- To identify how to handle complications scenarios

- Closing iatrogenesis: when a simple device saves both the patient... and the doctor
  P. De Araujo Goncalves
- TAVI in self-expanding bioprosthesis complicated by severe low flow status: The worst scenario
  P. Dardas
- Solving a “cold” case: severe aortic stenosis and paraaortic pseudoaneurysm
  R. Nerla
- The best is enemy of the good... especially when there is too much calcium
  J. Sanz Sánchez

**Hot line on PCI: high bleeding risk and DAPT - part 1**

- The ARC-HBR trade-off model
  P. Urban
- Validation of ARC HBR criteria
  M. Valgimigli
- Impact of HBR on prognosis after PCI
  H. Hioki
- Aspirin vs. P2Y12 monotherapy in Onyx-1
  A. Latib
- My analysis of HBR and DAPT studies
  F.J. Neumann

**PCR e-Course 2020**

**Late-Breaking Trials - part 1**

- Crossover results from the RADIANCE-HTN SOLO trial
  A. Kirtane
- Two-stent vs. provisional for bifurcation PCI: the DEFINITION II trial
  S.L. Chen

**The future of renal denervation: benefits of an ultrasound approach to renal denervation**

See session details in the Sponsored Programme section at the end of this document.

**Latest evidence from the RADIANCE-HTN trial and the path to clinical adoption**

See session details in the Sponsored Programme section at the end of this document.

**CTO procedures: the antegrade approach**

Facilitators: H.J. Buettner, K. Mashayekhi, P. Tajti
14:42 - 15:30  |  HOTLINE AND INNOVATION CHANNEL  
Focus on Innovation  
Hot line / Late-Breaking Trials  

14:42 | Hot line: TAVI - part 2

14:49 | Two-year outcomes from the PORTICO IDE trial
R. Makkar

14:56 | Impact of anticoagulant after TAVI
M. Gilard

15:04 | TAVI for bicuspid valves with Evolut
D. Tchétché

15:12 | VIVALL - One-year outcomes with a novel transcatheter heart valve
U. Schäfer

15:19 | My analysis of FlexNav, PORTICO IDE, France TAVI, BIVOLUT-X and VIVALL
D. Mylotte

15:40 - 16:30  |  INTERVIEWS AND ROUND TABLE CHANNEL  
Level  
Sponsored session  

15:40 | Last frontiers in treatment of high bleeding risk patients
See session details in the Sponsored Programme section at the end of this document.

15:24 - 16:10  |  MAIN ARENA CHANNEL  
Level  
Recorded LIVE  

15:24 | CTO procedures: the retrograde approach
Facilitators: H.J. Buettner, K. Mashayekhi, P. Tajti

15:30 - 16:15  |  CASE-BASED LEARNING CHANNEL  
Level  
Focus on Drugs and Devices Synergy  
Case Discussion  

15:30 | How to select the most appropriate DAPT strategy in each patient?
Attend this session if you want:
› To tailor DAPT strategies based on balance between ischaemic and bleeding risks in specific clinical situations
› To review the different options regarding drug choices, doses, and duration of treatment

15:30  |  Session objectives
T. Cuisset

15:40 | How did we learn from this case?
T. Cuisset, G. Cayla

15:53  |  What did we learn from this case?
T. Cuisset, J. Mehilli

16:06  |  What did we learn from this case?
J.P. Collet

16:11  |  What did we learn from this case?
J.P. Collet, T. Cuisset

14:45 - 15:30  |  CASE-BASED LEARNING CHANNEL  
Level  
Case Discussion  

14:45 | Non-culprit stenosis revascularisation in STEMI patients with multivessel disease: which, when and how?

Attend this session if you want:
› To understand how to invasively evaluate non-culprit stenosis in STEMI
› To discuss optimal timing of non-culprit PCI
› To understand how to implement novel evidence and guideline recommendations to your local practice

14:45  |  Session objectives
E. Barbato

14:48  |  What did we learn from this case?
E. Barbato, G. Campo

15:53  |  What did we learn from this case?
E. Barbato, T. Engstrom

16:06  |  What did we learn from this case?
E. Barbato, T. Engstrom

15:02  |  What did we learn from this case?
E. Barbato, G. Campo

15:12  |  What did we learn from this case?
E. Barbato, H. Thiele

15:24  |  What did we learn from this case?
E. Barbato, H. Thiele
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
</table>
| 15:30  | Hot line: revascularisation strategies                                         | International survey on Interventional Strategies 2.0
G. G Toth
The REDUCER-I study, narrowing of the coronary sinus
S. Verheye
NSTEMI >80 yrs - revascularisation or medical treatment - One-year death and MI
A. De Belder
Individualised decision-making between PCI and CAGB in patients with complex CAD
P.W. Serruys
My analysis of ISIS 2, Reducer study, and medical treatment vs. PCI vs. CAGB
M. Haude |
| 16:15  | The burden of non-COVID patients: caring for the left-behind                   | Speakers: I. Durand Zaleski, D. Holmes, M. Ntsekhe, G. Stefanini       |
| 16:15  | The PicSO therapy to reduce infarct size and clear microcirculation in STEMI patients | See session details in the Sponsored Programme section at the end of this document. |
| 16:15  | Transferring BIOSTEMI outcomes into daily practice - an expert discussion     | See session details in the Sponsored Programme section at the end of this document. |
| 16:30  | Low risk TAVI trials in the real world: where are we in 2020?                 | Partners in Learning: joint session between TVT and PCR
Attend this session if you want:
To fully appreciate the impact of the low risk TAVI trials
To understand how to apply this information in your daily clinical practice
To translate clinical trial outcomes into real-world decisions by your Heart Team |
| 16:30  | Session objectives                                                            | B. Prendergast |
| 16:33  | Case presentation: a 68 year-old patient with severe symptomatic aortic stenosis and a trileaflet aortic valve | F. Praz |
| 16:37  | The low-risk TAVI trials: current and future implications for everyday clinical practice | M. Mack |
| 16:45  | Heart Team Discussion: behind the headlines - Who was in the trials? And who was not? What is the best treatment option for this patient in 2020? | V. Bapat, M.B. Leon, B. Prendergast, L. Sondergaard |
| 17:07  | Case conclusion: how did the Heart Team proceed?                              | F. Praz |
| 17:10  | Session evaluation and key learnings                                          | M.B. Leon |
16:30 - 17:23
Hot line: CT guidance for coronary interventions

17:00 - 21:00
DEFINE FLAIR & SWEDEHEART
2-year deferred data

16:46 - 17:16
PCR e-Course 2020
Late-Breaking Trials - part 2

16:46 - 17:16
MAIN ARENA
Channel Level
Hot line / Late-Breaking Trials

17:15 - 18:00
Controversies in antiplatelet therapy for secondary prevention of coronary artery events

17:18 - 17:32
Merits of revascularisation and medical treatment in patients with chronic coronary syndromes
Speaker: D. Capodanno

CT-derived FFR for assessment of coronary haemodynamic ischaemia (CT-FFR CHINA)
B. Lu

CT-FFR in patients with severe aortic stenosis: the CAST-FFR trial
M. Michail

CT-QFR or myocardial perfusion imaging in patients with coronary stenosis on CTA
J. Westra

Effect of pre-procedural coronary CT angiography on the CTO success
B.K. Kim

CCTA for optimal fluoroscopic coronary projections
N. Piazza

My analysis of CT-guidance for PCI
D. Andreini

Two-year safety of revascularisation deferral based on iFR or FFR
J. Escaned

Discussion
F. Hellig

CABG and PCI in patients with CTO and multivessel disease
B. Xu

Discussion
W. Wijns

Routine revascularisation vs. medical therapy: meta-analysis and review
S. Bangalore

Discussion
D. Capodanno

See session details in the Sponsored Programme section at the end of this document.
TAVI patients and procedures in 2020 and beyond - leading with Evolut platform

See session details in the Sponsored Programme section at the end of this document.

To stent or not to stent? Discussion of complex PCI cases

See session details in the Sponsored Programme section at the end of this document.

Shaping care pathways for severe aortic stenosis patients in a COVID-19 context

See session details in the Sponsored Programme section at the end of this document.

Clip technology you know and trust, designed for the tricuspid valve

See session details in the Sponsored Programme section at the end of this document.

Key learnings of the day
Interventions for Valvular Disease
Coronary interventions
Interventions for Heart Failure
Interventions for Hypertension
Interventions for Stroke
Peripheral Interventions

CASE-BASED LEARNING CHANNEL
Level
Sponsored session

Portico FlexNav - Optimise TAVI outcomes from routine to complex cases
See session details in the Sponsored Programme section at the end of this document.

CASE-BASED LEARNING CHANNEL
Level
Case Discussion

Introduction of the day

MAIN ARENA CHANNEL
Level
Spotlight

Innovative solutions to treat diabetic patients
See session details in the Sponsored Programme section at the end of this document.

HOTLINE AND INNOVATION CHANNEL
Level
Focus on Drugs and Devices Synergy

Ultra low contrast: new skills and technologies for next frontier in PCI
See session details in the Sponsored Programme section at the end of this document.

HOTLINE AND INNOVATION CHANNEL
Level
Focus on Imaging

Tailoring mitral repair: new evidence demonstrating improved patient outcomes
See session details in the Sponsored Programme section at the end of this document.

CT guidance for coronary intervention and surgery
Attend this session if you want:
To appreciate how coronary CT can be used for selection of coronary revascularisation procedures
To discuss how coronary CT can help planning the procedural strategy for PCI of bifurcation and complex lesions

MAIN ARENA CHANNEL
Level
Spotlight

STEMI interventions: First-in-Man and novel pharmacological strategies

HOTLINE AND INNOVATION CHANNEL
Level
Focus on Drugs and Devices Synergy

Focus on Innovation
Hot line / Late-Breaking Trials

Dynamic Microvascular Resistance for measuring MVO treatment (MOCA I)
F. Gragnano
09:00

Impact of opioids on P2Y12-receptor inhibition in STEMI - The ON-TIME 3 trial
A. Tavenier
09:08

FABOLUS FASTER study
M. Valgimigli
09:15

My analysis of MOCA I, ON-TIME 3 and FABOLUS FASTER
C.K. Naber
09:22
**09:01 - 09:31**

**MAIN ARENA CHANNEL**

**Level**

Focus on Clinical Research

**Tutorial**

**How to understand the ISCHEMIA trial?**

Attend this session if you want:

- To get a better understanding of what is the ISCHEMIA trial about and what it is not about
- To make your own opinion on the strength of the ISCHEMIA conclusions based on its methodology and results
- To reflect on how much the results of ISCHEMIA will impact on your practice

**09:01**
- Introduction
  - D. Capodanno

**09:03**
- Trial anatomy: what is this trial about, and what is not?
  - R. Byrne

**09:11**
- Internal validity: are the trial conclusions supported by the evidence?
  - P. Juni

**09:19**
- External validity: will this trial change my practice?
  - R. Al-Lamee

**09:27**
- Concluding remarks
  - D. Capodanno

---

**09:33 - 10:35**

**MAIN ARENA CHANNEL**

**Level**

Recorded LIVE Case

**Procedural techniques for calcified lesions**

**Facilitators: E. Barbato, F. Ribichini**

Attend this session if you want:

- To identify calcified lesions that require plaque modification
- To differentiate the respective indications for different devices
- To comprehend the essential procedural steps for each tool

---

**09:45 - 10:30**

**CASE-BASED LEARNING CHANNEL**

**Level**

Case Discussion

**TAVI and the conduction system**

Attend this session if you want:

- To appreciate the factors that predict conduction abnormalities during TAVI (and how to avoid them)
- To understand which patients are at risk of late abnormalities and need prolonged monitoring after TAVI
- To identify which patients require permanent pacemaker implantation (and when)

**09:45**
- Session objectives
  - D. Mylotte

**09:48**
- TAVI - A patient with pre-existing RBBB
  - O. De Backer

**09:56**
- What did we learn from this case?
  - D. Mylotte, O. De Backer

**10:02**
- A patient with prolonged QRS duration immediately after TAVI
  - A.S. Petronio

**10:10**
- What did we learn from this case?
  - D. Mylotte, A.S. Petronio

**10:16**
- A patient with late high-degree conduction disturbance one week after TAVI
  - M. Urena

**10:24**
- What did we learn from this case?
  - D. Mylotte, M. Urena

---

**09:29 - 09:59**

**HOTLINE AND INNOVATION CHANNEL**

**Level**

Focus on Drugs and Devices

Synergy

Focus on Innovation

Hot line / Late-Breaking Trials

**Hot line: drugs and devices for STEMI management**

**09:29**
- Ultrathin-strut vs. thin-strut DES for primary PCI
  - J.F. Iglesias

**09:38**
- RCT between bioresorbable and durable polymer stent by serial OCT assessment
  - Y. Morino

**09:46**
- The FUNCOMBO trial
  - J. Gomez Lara

**09:54**
- My analysis of BIOSTEMI, different polymers and Biofreedom DES for STEMI
  - C. Tamburino

---

**09:59 - 10:28**

**HOTLINE AND INNOVATION CHANNEL**

**Level**

Focus on Imaging

Focus on Innovation

Cardiovascular Innovation Pipeline

**Physiology or intracoronary imaging; or both? or none? - part 1**

**Discussant: Z. Ali**

**09:59**
- Intravascular imaging to guide PCI: a SCAAR report
  - A. Silverio

**10:07**
- Deferral of PCI based on FFR or OCT findings: a subanalysis of the FORZA trial
  - A.M. Leone

**10:15**
- Diagnostic accuracy of IVUS-based FFR
  - S. Tu

**10:21**
- My analysis of physiology and imaging
  - Z. Ali
<table>
<thead>
<tr>
<th>Time</th>
<th>Channel</th>
<th>Focus on</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:28 - 10:58</td>
<td>HOTLINE AND INNOVATION CHANNEL Level</td>
<td>Focus on Innovation</td>
<td>Hot line: left atrial appendage closure</td>
<td>S. Windecker</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>CASE-BASED LEARNING CHANNEL Level</td>
<td>Focus on Drugs and Devices Synergy</td>
<td>Amulet IDE Roll-in cohort</td>
<td>J.E. Nielsen-Kudsk</td>
</tr>
<tr>
<td>10:45 - 10:51</td>
<td>MAIN ARENA CHANNEL Level</td>
<td>Sponsored session</td>
<td>Percutaneous edge-to-edge repair for tricuspid regurgitation: 1-year outcomes from the TRILUMINATE trial</td>
<td></td>
</tr>
<tr>
<td>10:53 - 10:58</td>
<td>MAIN ARENA CHANNEL Level</td>
<td>Sponsored session</td>
<td>How does the latest Tendyne TMVI clinical evidence change the way the heart team treats mitral regurgitation?</td>
<td></td>
</tr>
<tr>
<td>10:58 - 11:28</td>
<td>HOTLINE AND INNOVATION CHANNEL Level</td>
<td>Focus on Imaging</td>
<td>Physiology or intracoronary imaging; or both? or none? - part 2</td>
<td>J. Adjedj, A. Gupta, J. Sonck, R. Scarsini</td>
</tr>
</tbody>
</table>

**Saturday 27 June 2020**

**HOTLINE AND INNOVATION CHANNEL Level**

**Focus on Innovation**

**Hot line / Late-Breaking Trials**

- Amulet IDE Roll-in cohort
- LAA occlusion vs. novel oral anticoagulation
- A data mining approach for identification of potential LAAC candidates
- My analysis of LAA closure studies

**CASE-BASED LEARNING CHANNEL Level**

**Focus on Drugs and Devices Synergy**

- Onyx ONE: aspirin vs. P2Y12 after 1-month DAPT for high bleeding risk patients

**MAIN ARENA CHANNEL Level**

**Sponsored session**

- Dynamic coronary roadmap for contrast reduction (DCR4Contrast) trial
- See session details in the Sponsored Programme section at the end of this document.

**HOTLINE AND INNOVATION CHANNEL Level**

**Focus on Imaging**

- Cardiovascular Innovation Pipeline
- See session details in the Sponsored Programme section at the end of this document.

**CASE-BASED LEARNING CHANNEL Level**

**Focus on Imaging**

- Essentials of intracoronary imaging: the best use of your 50 probes
- Speakers: E. Mehanna, L. Räber, W. Wijns

**MAIN ARENA CHANNEL Level**

**Sponsored session**

- Percutaneous edge-to-edge repair for tricuspid regurgitation: 1-year outcomes from the TRILUMINATE trial
- See session details in the Sponsored Programme section at the end of this document.

- Essentials of intracoronary imaging: the best use of your 50 probes
- Speakers: E. Mehanna, L. Räber, W. Wijns

- How does the latest Tendyne TMVI clinical evidence change the way the heart team treats mitral regurgitation?
- See session details in the Sponsored Programme section at the end of this document.

- Physiology or intracoronary imaging; or both? or none? - part 2
- J. Adjedj, A. Gupta, J. Sonck, R. Scarsini
11:00 - 11:07
Blood pressure outcomes: renal denervation in various patients subgroups
See session details in the Sponsored Programme section at the end of this document.

11:09 - 11:14
New evidence in treating bicuspid TAVI patients: insights from Bivolut-X registry
See session details in the Sponsored Programme section at the end of this document.

11:15 - 12:00
CABG or PCI in patients with left main coronary artery disease
Attend this session if you want:
> To be updated on clinical outcomes in patients with left main lesion treated by PCI or CABG
> To understand the different criteria who play a major role in decision making between PCI and CABG
> To understand the relative merits of each revascularisation strategy

11:16 - 11:20
Evolut Low Risk randomised study 1 year results and economic implications
See session details in the Sponsored Programme section at the end of this document.

11:22 - 11:35
Vulnerable plaques and vulnerable patients
Speaker: M. Tomaniak

11:28 - 11:59
Hot line on PCI: high bleeding risk and DAPT - part 2

11:15
Session objectives
J. Fajadet

11:18
Updated overview of clinical outcomes in patients with left main coronary artery disease: evidence and experience from trials and registries
S. Windecker

11:28
Individualised decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: redevelopment and validation of the SYNTAX score II 2020
P.W. Serruys

11:38
The clinical realities of left main coronary artery disease
T. Johnson

11:43
What's in favour of PCI
J. Fajadet

11:48
What's in favour of surgery
M. Andreas

11:53
How we treated our patient and what was the outcome
T. Johnson

11:58
Session evaluation and key learnings
J. Fajadet

11:28
Ticagrelor with or without aspirin in Chinese patients undergoing PCI
R. Mehran

11:40
Short DAPT after biodegradable polymer-coated ultrathin sirolimus-eluting stents
J.Y. Hahn

11:48
Biolimus-A9 coated thin strut stent in high bleeding risk patients
F. Eberli

11:55
My analysis of DES for HBR
M. Gilard
The year in intervention: 
estential publications from 
EuroIntervention and the 
European Heart Journal

Attend this session if you want:
› To evaluate the academic versus social 
impact of your publications
› To discover the most often quoted 
articles of the year

11:37  › Session objectives
       D. Capodanno

11:39  › What do people cite? Top three original 
       articles since the last EuroPCR
       European Heart Journal
       F. Crea

11:48  › EuroIntervention
       R. Byrne

11:57  › What do people discuss? Top three original 
       articles since the last EuroPCR
       EuroIntervention
       S. Brugaletta

12:06  › European Heart Journal
       R. Ladeiras-Lopes

12:15  › Academic metrics for cardiovascular 
       journals: from the impact factor to 
       Altmetrics
       T.F. Lüscher

12:25 - 12:35  Closing
Detailed Sponsored Programme
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 20:30</td>
<td>Latest insights from the ReCre8 randomised trial</td>
<td>Supported by an educational grant from Alvimedica</td>
</tr>
<tr>
<td></td>
<td>Session coordinator: G. Sardella Speaker: P. Stella</td>
<td>Attend this session if you want:</td>
</tr>
<tr>
<td></td>
<td>› To know the outcome of the ReCre8 troponine-patients subgroup, who received 1month DAPT, according to the new HBR classification (ARC consensus).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>› To know the outcome of the ReCre8 diabetic subgroup according to the implanted DES - Resolute or Cre8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>› To understand how strongly safety &amp; efficacy are interconnected in HBR patients (very complex patients) and how a Safe DES able to have superior Efficacy would optimize the outcome in HBR patients</td>
<td></td>
</tr>
</tbody>
</table>

| Time         | Benefits of ultrathin DES in complex bifurcations - case based expert discussion                  | Supported by an educational grant from Biotronik                                                                                 |
|              | Session coordinator: P.H.L. Kao Speakers: J. Bennett, M.C. Brandt                                 | Attend this session if you want:                                                                                                     |
|              | › To assess the role of ultrathin DES in bifurcation treatment                                    | › To learn about advancements in the Medtronic renal denervation procedure with the Spyral catheter                                  |
|              | › To experience innovation in practice                                                              | › To hear up-to-date data behind ablating the renal artery branches                                                                  |
|              | › To learn techniques for optimising outcomes in complex bifurcations                               | › To learn about the science behind RF renal denervation                                                                             |
|              |                                                                                                   | › To understand future procedural advancements                                                                                     |

| Time         | Latest experience with PiCSO in STEMI patients                                                    | Supported by an educational grant from Miracor Medical                                                                              |
|              | Session coordinator: A. Baumbach Speaker: G.L. De Maria                                           | Attend this session if you want:                                                                                                     |
|              | › To learn about the latest OxAMI-PiCSO study clinical results                                    | › To understand the challenges of treating eccentric calcium                                                                          |
|              | › To learn about the first-in-man of PiCSO in inferior STEMI patients                             | › To learn about the initial IVL clinical experience in eccentric calcium                                                            |
|              |                                                                                                   | › To realise best practices when treating eccentric calcium with IVL                                                                     |

| Time         | LAA occlusion vs. novel oral anticoagulation in atrial fibrillation                                | Supported by an educational grant from Abbott                                                                                      |
|              | Speaker: J.E. Nielsen-Kudsk                                                                        | Attend this session if you want:                                                                                                     |
|              | › To learn which patients may benefit from LAAO vs. long term OAC                                   | › To learn about the latest data of LAAO vs NOAC from a substantial cohort in a propensity score matched study and what impact it might have medium and longer term |

| Time         | Advances in the renal denervation procedure                                                        | Sponsored by Medtronic                                                                                                             |
|              | Speaker: A. Sharp                                                                                  | Attend this session if you want:                                                                                                     |
|              | › To learn about advancements in the Medtronic renal denervation procedure with the Spyral catheter | › To hear up-to-date data behind ablating the renal artery branches                                                                  |
|              | › To learn about the science behind RF renal denervation                                            | › To understand future procedural advancements                                                                                     |

| Time         | Shockwave IVL Safety and Performance in Eccentric Calcified Coronary Lesions                      | Sponsored by Shockwave Medical                                                                                                     |
|              | Speaker: H. Nef                                                                                   | Attend this session if you want:                                                                                                     |
|              | › To learn about advancements in the Medtronic renal denervation procedure with the Spyral catheter | › To hear up-to-date data behind ablating the renal artery branches                                                                  |
|              | › To learn about the initial IVL clinical experience in eccentric calcium                           | › To learn about the science behind RF renal denervation                                                                             |
|              | › To realise best practices when treating eccentric calcium with IVL                               | › To understand future procedural advancements                                                                                     |

<p>| Time         | Results from XTOSI Trial: MagicTouch SCB - Future Alternative for PVD Treatment                   | Sponsored by Concept Medical                                                                                                       |
|              | Session coordinator: S. Parikh Speakers: E. Choke, U. Teichgräber                                 | Attend this session if you want:                                                                                                     |
|              | › To learn about Efficacy and Safety of Magic Touch Sirolimus-Coated Balloon                      | › To learn about the initial IVL clinical experience in eccentric calcium                                                            |
|              | › To learn the valid alternative for treatment of Peripheral Vascular Disease                    | › To realise best practices when treating eccentric calcium with IVL                                                                     |
|              | › To present XTOSI trial results, a FIM SFA and BTK Trial and upcoming Trial from Singapore and Germany |                                                                                                                                           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Sponsored by</th>
<th>Session Coordinator</th>
<th>Speakers</th>
<th>Attend if you want</th>
</tr>
</thead>
</table>
| 16:00 - 20:30| Microcatheter-based coronary physiology: where and how                         | Insight Lifetech              | E. Barbato          | S. Brugaletta, C. Collet                   | To understand the current role of microcatheter-based physiology in the diagnostic evaluation of coronary stenosis  
To discuss how to spare resources by using physiology tools as work-horse PCI devices  
To learn how to safely and accurately optimize stent implantation by post-PCI microcatheter-based invasive physiology |
| 16:00 - 20:30| The new paradigm for coronary interventions                                    | M.A. Med Alliance             | S. Windecker        | R. Byrne, R. Costa                         | To understand indications for DEB vs. DES and the potential advantage of a sustained sirolimus release when utilised in a DEB  
To get insights into the breakthrough technology of the SELUTION SLR and its initial clinical data and clinical experience  
To review the relevance of the concept leaving nothing behind and the importance of vessel preparation |
| 16:00 - 20:30| LAA occlusion vs. novel oral anticoagulation in atrial fibrillation             | Abbott                        | U. Landmesser       | D. Hildick-Smith, S. Windecker             | To learn about which patients may benefit from LAA occlusion vs. long term anticoagulation  
To learn about the latest data of LAAO vs. NOACs from a substantial cohort in a propensity score matched study |
| 16:00 - 20:30| Proximal optimisation technique (POT) in bifurcation stenting                 | Medtronic                     | G. Stankovic        | J.F. Lassen                                | To learn why POT is important in bifurcation PCI and how to perform it correctly  
To review the pitfalls of POT and how to avoid them |
| 16:00 - 20:30| The unique challenges of left main PCI                                         | Medtronic                     | G. Stankovic        | F. Burzotta                                | To understand why the left main PCI approach and techniques are unique to the anatomy  
To understand the EBC consensus and other evidence on left main PCI  
To review a left main PCI real world case |
| 16:00 - 20:30| Addressing the population question - interesting case profiles in renal denervation | Medtronic                     | J. Weil             | I. Sudano                                  | To learn about the prevalence and importance of non-adherence to hypertension medication and the role of patient preference  
To learn about renal denervation as an option for both non-adherent and high-risk patients |
<p>| 16:00 - 20:30| Renal denervation: putting guidelines into practice                           | Medtronic                     | F. Ribichini        | T.D. Wang                                  | To learn about patient identification tools in various geographies and how they are implemented in clinical practice. |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speakers</th>
<th>Coordinator</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 20:30</td>
<td>TAVI implantation optimisation - Practical aspects of cusp overlap technique</td>
<td>D. Mylotte</td>
<td>L. Sondergaard</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To learn about the contemporary cusp overlap implantation technique</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand the practical aspects of how the cusp overlap technique can increase procedural predictability and reduce PPI rates</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Post-TAVI PCI access - The essentials</td>
<td>G. Manoharan</td>
<td>D. Mylotte</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To discuss procedural tips and tricks to achieve PCI access after TAVI valve implantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To demonstrate practical post-TAVI PCI access case examples</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Treating bicuspid valve anatomy - evidence and practice</td>
<td>D. Tchétché</td>
<td>L. Sondergaard</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To learn about the latest clinical data on treating bicuspid aortic valves</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To learn about the contemporary techniques, practical aspects and implications in treating bicuspid aortic valves</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Durability of Transcatheter Aortic Valves</td>
<td>L. Sondergaard</td>
<td>L. Sondergaard</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To learn about current relevant questions and challenges regarding transcatheter aortic valve durability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To learn about the latest evidence on structural valve deterioration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To discuss how to improve valve durability in the individual patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>The dynamic landscape of mitral interventions in 2020</td>
<td>T. Modine</td>
<td>L. Sondergaard</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand learnings from early clinical studies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To review who is not the optimal patient for mitral repair</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Latest advances in CTO techniques</td>
<td>B. Zhang</td>
<td>B. Zhang</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To learn Stumpless CTO Recanalization Using IVUS Guided Antegrade Approach. Well begun is half done.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand Ipsilateral Retrograde Recanalization All roads lead to Roma.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To gain insight of ‘ESC’ Principle &amp; Invisible septal surfing skill. Beyond the sight, beyond the imagination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Evidence based PCI in patients at high bleeding risk - The LEADERS FREE trials</td>
<td>K.G. Oldroyd</td>
<td>K.G. Oldroyd</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand the importance of high bleeding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand the safety and efficacy of polymer free BA9-coated coronary stents</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand the impact of a new thin strut CoCr stent platform on clinical outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Sponsored session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 20:30</td>
<td>Use of IVUS+NIRS imaging for decision making in ACS</td>
<td>G. Guagliumi</td>
<td>G. Guagliumi</td>
<td>Medtronic</td>
</tr>
<tr>
<td></td>
<td>Attend this session if you want:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To be informed about the frequency of culprit lesion ambiguity in ACS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To clarify the value of IVUS+NIRS imaging in challenging scenarios</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>To understand how to integrate the information provided by IVUS+NIRS imaging in the clinical decision-making process</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Level: Focus on Imaging</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Thursday 25 June 2020

- Interventions for Valvular Disease
- Coronary interventions
- Interventions for Heart Failure
- Interventions for Hypertension
- Interventions for Stroke
- Peripheral Interventions
Thursday 25 June 2020

17:24 - 17:34  Commando not required
"Imaging for complex structural heart interventions"
Supported by an educational grant from GE Healthcare
Session coordinator: R. Rajani
Speaker: S. Redwood
Attend this session if you want:
› To understand the imaging planning steps for a high-risk sequential TAVR and valve in MAC case
› To learn how CT/Fluoroscopic fusion is used in real time to guide complex structural interventions
› To learn interventional procedural tips and tricks for a valve in MAC case

17:30 - 17:45  A pivotal moment for renal denervation
Sponsored by Medtronic
Session coordinator: K. Tsioufis
Speaker: M. Böhm
Attend this session if you want:
› To revisit the clinical evidence behind the Medtronic renal denervation programme
› To hear the new Pivotal OFF MED result

17:36 - 17:42  How to easily reduce radiation exposure in your cathlab? 5 minutes to convince
Supported by an educational grant from GE Healthcare
Speakers: R. Didier, M. Gilard
Attend this session if you want:
› To understand how to maintain the receptor close to the patient
› To use a 3.75 frame rate during the procedure
› To evaluate easily the skin dose received by your patient

17:44 - 17:49  Robotic PCI programme in IGS 5 environment
Supported by an educational grant from GE Healthcare
Speaker: J. Fajadet

19:00 - 19:45  SYNERGY MEGATRON - Transforming your left main bifurcation strategy for improved outcomes
Sponsored by Boston Scientific
Session coordinator: T. Lefevre
Speakers: J.M. De La Torre Hernandez, S. Walsh
Attend this session if you want:
› To review steps for PCI in complex left main bifurcation lesions
› To advance your knowledge on IVUS-guided PCI in left main disease
› To learn about a purpose-built new stent platform for large vessels and left main

19:00  Session objectives
T. Lefevre
19:02  Case introduction - Complex left main bifurcation
S. Walsh
19:07  Discussion
J.M. De La Torre Hernandez, T. Lefevre, S. Walsh
19:12  Crash course on IVUS guidance for left main PCI
J.M. De La Torre Hernandez
19:22  Discussion
J.M. De La Torre Hernandez, T. Lefevre, S. Walsh
19:27  Case conclusion
S. Walsh
19:37  Discussion
J.M. De La Torre Hernandez, T. Lefevre, S. Walsh
19:42  Session evaluation and key learnings
T. Lefevre

19:00 - 19:45  How the interventional cardiologist should approach patients with a vasculogenic erectile dysfunction?
Supported by an educational grant from Concept Medical
Session coordinator: R. Mehran
Speakers: N. Diehm, G. Sangiorgi
Attend this session if you want:
› To learn how Cardiologist should approach the patients with ED
› To see how to treat a patient with ED with Sirolimus Coated Balloon
19:00 - 20:30

**INTERVIEWS AND ROUND TABLE CHANNEL**

**Level**

**Sponsored session**

**Target all comers outcomes update**
Sponsored by MicroPort
Session coordinator: A. Baumbach
Speakers: A. Lansky, W. Wijns

Attend this session if you want:
- To review the Firehawk family TES technology and early clinical outcomes
- To gain the first sight of the 3-year results of the TARGET AC trial
- To look into the Future Directions of Target series clinical trials

19:45 - 20:45

**CASE-BASED LEARNING CHANNEL**

**Level**

**Sponsored session**

**Selection of appropriate devices for retrograde CTO cases**
Supported by an educational grant from Asahi Intecc
Session coordinator: M. Yamane
Speakers: P. Knaapen, K. Mashayekhi

Attend this session if you want:
- To witness appropriate device selection for retrograde approach
- To improve your skills as a CTO operator
- To have interactive discussions about available CTO wires and devices

19:19 - 20:00

**MAIN ARENA CHANNEL**

**Level**

**Sponsored session**

**Best real-world applications of Shockwave intravascular lithotripsy (IVL) in coronary calcium**
Sponsored by Shockwave Medical
Session coordinator: B. Honton
Speakers: J. Escaned, M.K.Y. Lee

Attend this session if you want:
- To understand how intravascular lithotripsy works through real-world cases
- To hear from global leading physicians about where intravascular lithotripsy fits into their clinical practice
- To hear about some of the most prominent cases of coronary intravascular lithotripsy

19:45 - 20:30

**HOTLINE AND INNOVATION CHANNEL**

**Level**

**Focus on Imaging**

**Sponsored session**

**FFR wires passé? Rethinking the physiological assessment of coronary artery disease**
Supported by Siemens Healthineers
Speakers: Z. Ali, M.J. Gallagher, A. Jeremias

Attend this session if you want:
- To learn how to identify the hemodynamic relevance of intermediate coronary lesions with highest diagnostic accuracy to allow individualized therapy
- To learn about the new technology of coronary angiography derived FFR & its clinical potential
- To learn what is mandatory to get reliable CT FFR results

20:02 - 20:48

**MAIN ARENA CHANNEL**

**Level**

**Sponsored session**

**Are Lower MR Grades Within Our "Clasp"? - PASCAL Repair System Experience**
Supported by an educational grant from Edwards Lifesciences
Session coordinator: P. Lurz
Speakers: S. Lim, H. Nef
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
</table>
| 12:16 - 13:16 | **Coronary Microvascular Dysfunction: Why diagnosis in the Cathlab does matter**  
Supported by an educational grant from Abbott  
Session coordinator: B. De Bruyne  
Speakers: C. Berry, A. Chieffo, T. Gori  
Attend this session if you want:  
› To learn more about the prevalence of coronary microvascular dysfunction and angina  
› To learn why diagnosis of coronary microvascular dysfunction is so important  
› To learn how to correctly diagnose patients with coronary microvascular dysfunction  
12:16  
Introduction and session objectives  
B. De Bruyne  
12:19  
Coronary microvascular dysfunction - Is there more than what we can see?  
C. Berry  
12:27  
Discussion  
12:32  
Case presentation: no angiographic obstruction - The end or the beginning?  
T. Gori  
12:39  
Discussion between speakers  
12:44  
Case presentation: persistent angina - A real problem often neglected?  
A. Chieffo  
12:51  
Discussion  
12:56  
Session evaluation and key learnings  
B. De Bruyne |
| 12:30 - 13:15 | **Current evidence for the interventional treatment of NOCA patients**  
Supported by an educational grant from Neovasc  
Session coordinator: S. Banai  
Speakers: C. Berry, F. Giannini, T. Gori  
Attend this session if you want:  
› To understand when Reducer therapy can be a tool for the interventionalist to improve symptoms of “end stage” patient with a low level of procedural risk  
› To recognise when a patient is diagnosed with “refractory angina” in the cathlab and understand how Reducer therapy can address these patients with a low level of procedural risk  
› To recognise when patients with angina and non obstructive CAD (ANOCA) are at a high level of prognostic risk  
12:30  
Patient with severe refractory angina and current results of the REDUCER-1 study  
S. Banai  
12:41  
Single lesion patient with nonsignificant FFR  
F. Giannini  
12:52  
ANGINA with no obstructive coronary artery disease  
C. Berry  
13:03  
Patients with microvascular angina with and without CS pressure elevation  
T. Gori |
| 12:30 - 13:15 | **Sirolimus-coated balloons, an appraisal on its potential advantages over paclitaxel**  
Supported by an educational grant from Concept Medical  
Session coordinator: A. Colombo  
Speakers: S. Basavarajaiah, B. Cortese  
Attend this session if you want:  
› To learn and understand how and where to use a Sirolimus DCB in current practice  
› To see clinical evidences and results for the treatment of Patients with Sirolimus DCB  
› To see the potential advantages of using the Sirolimus over Paclitaxel  
12:30  
Patient with severe refractory angina and current results of the REDUCER-1 study  
S. Banai  
12:41  
Single lesion patient with nonsignificant FFR  
F. Giannini  
12:52  
ANGINA with no obstructive coronary artery disease  
C. Berry  
13:03  
Patients with microvascular angina with and without CS pressure elevation  
T. Gori |
Do drug-coated balloons prevail?
Sponsored by Medtronic
Speaker: A. Latib
Attend this session if you want:
› To discover the PREVAIL trial results and the implications for drug-coated balloons

Mastering complex calcified aortic stenosis
Sponsored by Boston Scientific
Session coordinator: L. Sondergaard
Speakers: M. Abdel-Wahab, D. Tchétché
Attend this session if you want:
› To advance your knowledge in imaging assessment of complex calcified aortic stenosis
› To review steps for TAVI in complex calcified aortic stenosis
› To learn about device selection and implantation technique in calcified anatomies

How to treat complex bifurcation lesions? From bench to being
Supported by an educational grant from Terumo
Session coordinator: T. Johnson
Speakers: B. Chevalier, T. Lefevre
Attend this session if you want:
› To understand the best treatment options for patients presenting with complex bifurcation lesion
› To share a benchtop simulation of bifurcation techniques
› To learn how to optimise both strategy and technique

New TMVI therapy to eliminate mitral regurgitation. Evidence and patient selection
Supported by an educational grant from Abbott
Session coordinator: N. Dumonteil
Speakers: L. Conradi, A. Duncan
Attend this session if you want:
› To get the latest update on the first commercially available TMVI therapy (Tendyne)
› To learn about Tendyne clinical experience and how to identify the best candidates for this novel therapy

The future of renal denervation: benefits of an ultrasound approach to renal denervation
Supported by ReCor Medical
Speaker: P. Lurz
Attend this session if you want:
› To gain a review of the current renal denervation therapies and how the latest results from the RADIANCE-HTN SOLO cohort should influence patient selection
› To review the potential benefits of the ultrasound approach to renal denervation
<table>
<thead>
<tr>
<th>Time</th>
<th>Channel</th>
<th>Session Title</th>
<th>Coordinator(s)</th>
<th>Speakers</th>
<th>Details</th>
</tr>
</thead>
</table>
| 14:30 - 19:30   | Interviews and Round Table Channel         | Latest evidence from the RADIANCE-HTN trial and the path to clinical adoption | Sponsored by ReCor Medical                  | Session coordinator: F. Mahfoud                                               | Speakers: M. Azizi, A. Kirtane                                                                                                              | Attend this session if you want:  
  - To learn about the latest results from the RADIANCE-HTN SOLO cohort  
  - To review blood pressure results following crossover to ultrasound renal denervation in patients originally randomised to the sham arm in RADIANCE-HTN SOLO  
  - To learn about the ABPM drops for these patients at the 2M and 6M time points  
  - To learn how these results apply to patient selection, therapy development and initial clinical adoption |
| 15:00 - 18:30   | Interviews and Round Table Channel         | Last frontiers in treatment of high bleeding risk patients                     | Supported by an educational grant from Terumo | Session coordinator: D. Capodanno                                              | Speakers: K. Kozuma, P. Smits, M. Valgimigli                                                                                                  | Attend this session if you want:  
  - To learn from experts the complexity of HBR patients  
  - To discover newest data on DAPT in this population  
  - To get first-hand update on upcoming major development in DAPT for HBR patients |
| 16:15 - 16:30   | Hotline and Innovation Channel             | Transferring BIOSTEMI outcomes into daily practice - an expert discussion     | Sponsored by Biotronik                       | Session coordinator: S. James                                                 | Speakers: J.F. Iglesias, G.G. Secco                                                                                                         | Attend this session if you want:  
  - To review the role of ultrathin DES in optimising clinical outcomes for STEMI patients  
  - To assess the impact of the BIOSTEMI trial to daily practice  
  - To learn about real-world challenges when treating STEMI patients |
| 16:29 - 16:44   | Main Arena Channel                        | The power of BIG DATA for PCI in practice                                     | Supported by an educational grant from Terumo | Session coordinator: M. Roffi                                                  | Speakers: B. Chevalier, M. Mamas                                                                                                           | Attend this session if you want:  
  - To understand the value of BIG DATA from global registries in interventional cardiology  
  - To explore regional differences in PCI and potential impact on clinical outcomes  
  - To learn how large registry data can impact your practice |
| 17:00 - 21:00   | Interviews and Round Table Channel         | DEFINE FLAIR & SWEDHEART 2-year deferred data                               | Sponsored by Philips                         | Session coordinator: D. Capodanno                                              | Speaker: J. Escaned                                                                                                                             | Attend this session if you want:  
  - To learn about iFR in the cathlab - the importance of over/under treatment and its implications  
  - To hear about the importance of physiology while managing patients post COVID outbreak  
  - To learn more about how deferral data of DF&SH combined 2yr result can impact practice in real world |
Controversies in antiplatelet therapy for secondary prevention of coronary artery events

Sponsored by AstraZeneca coordinated by AcademicCME

Session coordinator: C. Pollack
Speakers: T. Geisler, P.G. Steg, R. Storey, U. Zeymer

Attend this session if you want:
- To understand more about the guidelines for antiplatelet secondary prevention of ACS/PCI
- To review available data on antiplatelet therapy after ACS/PCI
- To learn about recent trials of antiplatelet therapies in ACS

Treating Tricuspid Regurgitation With The PASCAL Repair System

Supported by an educational grant from Edwards Lifesciences

Session coordinator: J. Hausleiter
Speakers: P. Lurz, R.S. Von Bardeleben

TAVI patients and procedures in 2020 and beyond - leading with Evolut platform

Sponsored by Medtronic

Session coordinator: L. Sondergaard
Speakers: D. Tchéché, N. Van Mieghem

Attend this session if you want:
- To learn about the different needs of TAVI patients with longer life expectancy and how to meet them
- To learn about the importance of haemodynamics and DVI correlation to mortality in TAVI patients
- To learn practical procedural tips and techniques to achieve superior outcomes and early discharge in a changing TAVI patient landscape

Introduction and session objectives
L. Sondergaard

Hemodynamics and DVI correlation to mortality - what we need to know
N. Van Mieghem

Discussion

TAVI procedure optimisation and new techniques to achieve early patient discharge
D. Tchéché

Discussion

Patient life expectancy vs. the expected durability of TAVI valves - knowns and unknowns
L. Sondergaard

Discussion

Session evaluation and key learnings
D. Tchéché
18:00 - 18:45

**CASE-BASED LEARNING CHANNEL**

**Level**

**Sponsored session**

**To stent or not to stent? Discussion of complex PCI cases**

Sponsored by B.Braun Melsungen AG

**Session coordinator:** M.A. Rosli

**Speakers:** S. Eccleshall, B. Scheller

**Attend this session if you want:**
- To join a detailed discussion about the DES vs. DCB approach
- To discuss the importance of lesion preparation for optimal PCI results
- To share insights about state-of-the-art treatment options from leading experts

18:00
- Session objectives
  M.A. Rosli

18:03
- Case 1 - Treatment of de novo proximal LAD - case history
  M.A. Rosli

18:06
- Discussion on treatment strategy, instruments and procedural aspects
  S. Eccleshall, M.A. Rosli, B. Scheller

18:16
- Case 1 - Presentation of treatment and long-term results
  M.A. Rosli

18:23
- Case 2 - Treatment of a LAD bifurcation in a diabetic patient with ACS - case history
  S. Eccleshall

18:26
- Discussion on treatment strategy, instruments and procedural aspects
  S. Eccleshall, M.A. Rosli, B. Scheller

18:36
- Case 2 - Presentation of treatment and long-term results
  S. Eccleshall

18:43
- Session summary and key learnings
  M.A. Rosli

---

18:18 - 18:45

**MAIN ARENA CHANNEL**

**Level**

**Sponsored session**

**Clip technology you know and trust, designed for the tricuspid valve**

Supported by an educational grant from Abbott

**Session coordinator:** G. Nickenig

**Speakers:** F. Praz, R.S. Von Bardeleben

**Attend this session if you want:**
- To learn why diagnosis and treatment of tricuspid regurgitation is the next transcatheter valvular treatment frontier
- To learn more about TriClip, novel therapy option for patients suffering from tricuspid regurgitation
- To learn about patient selection and ensure procedural success

18:18
- Session objectives
  G. Nickenig

18:23
- Tricuspid regurgitation, disease burden and necessity for treatment
  F. Praz

18:33
- TriClip dedicated treatment option for patients with tricuspid regurgitation
  G. Nickenig

18:43
- Overview of the TriClip procedure
  R.S. Von Bardeleben

18:58
- Session evaluation and key learnings
  G. Nickenig

---

18:00 - 18:45

**HOTLINE AND INNOVATION CHANNEL**

**Level**

**Sponsored session**

**Shaping care pathways for severe aortic stenosis patients in a COVID-19 context**

Supported by an educational grant from Edwards Lifesciences

**Session coordinator:** B. Prendergast

**Speakers:** N. Ruparelia, F. Saia, D.A. Wood

---

**Interventions for Valvular Disease**  **Coronary interventions**  **Interventions for Heart Failure**  **Interventions for Hypertension**  **Interventions for Stroke**  **Peripheral Interventions**
Portico FlexNav - Optimise TAVI outcomes from routine to complex cases
Supported by an educational grant from Abbott
Session coordinator: L. Sondergaard
Speakers: H. Möllmann, M. Mullen

Attend this session if you want:
- To learn how Portico enables you to achieve favorable haemodynamics and patient outcomes
- To learn about the new Portico with FlexNav TAVI system and its deliverability
- To learn the importance of looking ahead during TAVI and ensuring patients coronary access preservation

07:30 - 08:15
CASE-BASED LEARNING CHANNEL Level

07:30  Session objectives  L. Sondergaard
07:32  Portico with FlexNav latest clinical evidence and procedural benefits  H. Möllmann
07:40  Discussion
07:44  Innovation at its best, new Portico with FlexNav TAVI system  L. Sondergaard
07:52  Discussion
07:56  Portico with FlexNav procedural highlights  M. Mullen
08:09  Discussion
08:13  Session evaluation and key learnings  L. Sondergaard

Innovative solutions to treat diabetic patients
Supported by an educational grant from Concept Medical
Session coordinator: A. Abizaid
Speakers: M.C. Morice, L. Testa

Attend this session if you want:
- To understand the need of dedicated DES for Diabetes Mellitus (DM) patients
- To understand and learn the differences of CAD for diabetic compared to non-diabetic patients
- To see clinical evidences and results for the treatment of Diabetic patients with DES+
- To learn about the Largest Diabetic RCT for DES in decades

08:15 - 09:00
HOTLINE AND INNOVATION CHANNEL Level

08:15  Importance of minimal use of contrast and which technologies can support that  G. Stankovic
08:18  Role of imaging and co-reg in patients with kidney insufficiency  D. Dudek
08:28  Technological developments facilitating ultra-low contrast PCI  J. Escaned
08:38  IVUS Co-registration and MVD in LMS bifurcation  B. Patel
08:48  Discussion and take-home messages  D. Dudek, J. Escaned, B. Patel, G. Stankovic

Ultra low contrast: new skills and technologies for next frontier in PCI
Supported by an educational grant from Philips
Session coordinator: G. Stankovic
Speakers: D. Dudek, J. Escaned, B. Patel

Attend this session if you want:
- To learn why ultra low contrast PCI (ULCPCI) will be needed for patients who have developed cardiomyopathy due wait linked to COVID outbreak
- To understand what tools we have in the cathlab to perform ultra-low contrast PCI
- To learn how to practice ultra-low contrast in multivessel disease and CTO

- Importance of minimal use of contrast and which technologies can support that  G. Stankovic
- Role of imaging and co-reg in patients with kidney insufficiency  D. Dudek
- Technological developments facilitating ultra-low contrast PCI  J. Escaned
- IVUS Co-registration and MVD in LMS bifurcation  B. Patel
- Discussion and take-home messages  D. Dudek, J. Escaned, B. Patel, G. Stankovic

08:15 - 09:00
CASE-BASED LEARNING CHANNEL Level
Focus on Imaging

Tailoring mitral repair: new evidence demonstrating improved patient outcomes
Supported by an educational grant from Abbott
Session coordinator: F. Maisano
Speakers: S. Kar, M. Sitges

Attend this session if you want:
- To tailor the mitral valve repair and optimise treatment based on etiology and mitral valve anatomy
- To learn about current MitraClip clip options as well as look into the future of the mitral repair treatment

- Session objectives  F. Maisano
- Learnings from largest contemporary real-world, all comer mitral repair outcomes: EXPAND  S. Kar
- Tailoring mitral valve repair: evidence based recommendation for clip selection  F. Maisano
- Importance of appropriate mitral valve leaflet visualisation for outcomes  M. Sitges
- What does the mitral valve repair future hold?  S. Kar
- Session evaluation and key learnings  F. Maisano
<table>
<thead>
<tr>
<th>Time</th>
<th>Channel</th>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>CASE-BASED LEARNING</td>
<td>Level</td>
<td>Onyx ONE: aspirin vs. P2Y12 after 1-month DAPT for high bleeding risk patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Session coordinator: A. Latib</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: E. Kedhi</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attend this session if you want:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To review the highlights of the Onyx ONE Month DAPT Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To listen to commentary on the SAPT late breaker sub-analysis comparing the safety and efficacy of administering aspirin vs. P2Y12 inhibitor</td>
</tr>
<tr>
<td>10:37 - 10:43</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>Dynamic coronary roadmap for contrast reduction (DCR4Contrast) trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Philips</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: J. Escaned</td>
</tr>
<tr>
<td>10:45 - 10:51</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>Percutaneous edge-to-edge repair for tricuspid regurgitation: 1-year outcomes from the TRILUMINATE trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Supported by an educational grant from Abbott</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: P. Lurz</td>
</tr>
<tr>
<td>10:53 - 10:58</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>How does the latest Tendyne TMVI clinical evidence change the way the heart team treats mitral regurgitation?</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Supported by an educational grant from Abbott</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: D. Muller</td>
</tr>
<tr>
<td>11:00 - 11:07</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>Blood pressure outcomes: renal denervation in various patients subgroups</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: P. De Araujo Goncalves</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attend this session if you want:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To learn about long-term data demonstrating the safety and efficacy of renal denervation in various patient subgroups, including those with chronic kidney disease</td>
</tr>
<tr>
<td>11:09 - 11:14</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>New evidence in treating bicuspid TAVI patients: insights from Bivolut-X registry</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: D. Tchéché</td>
</tr>
<tr>
<td>11:16 - 11:20</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>Evolut Low Risk randomised study 1 year results and economic implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: M. Reardon</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attend this session if you want:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To discuss key take-aways from the economic analysis and the health economics implications for Europe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To understand the potential drivers for TAVI cost-effectives in Europe</td>
</tr>
<tr>
<td>11:16 - 11:20</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>Blood pressure outcomes: renal denervation in various patients subgroups</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: P. De Araujo Goncalves</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attend this session if you want:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To learn about long-term data demonstrating the safety and efficacy of renal denervation in various patient subgroups, including those with chronic kidney disease</td>
</tr>
<tr>
<td>11:16 - 11:20</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>New evidence in treating bicuspid TAVI patients: insights from Bivolut-X registry</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: D. Tchéché</td>
</tr>
<tr>
<td>11:16 - 11:20</td>
<td>MAIN ARENA</td>
<td>Level</td>
<td>Evolut Low Risk randomised study 1 year results and economic implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sponsored by Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Speaker: M. Reardon</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attend this session if you want:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To discuss key take-aways from the economic analysis and the health economics implications for Europe</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>➤ To understand the potential drivers for TAVI cost-effectives in Europe</td>
</tr>
</tbody>
</table>